Quetiapine: Difference between revisions
| [unchecked revision] | [unchecked revision] |
Assign pharmacological categories from List_of_CNS-active_medicines |
MDElliottMD (talk | contribs) Dedupe migration per interface-claude 2026-05-20: Antipsychotics / Neuroleptics merged into canonical Neuroleptics. Member retagged. |
||
| Line 31: | Line 31: | ||
}} | }} | ||
[[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]] | [[Category:Second-Generation Antipsychotics (SGAs / Atypicals)]] | ||
[[Category:Neuroleptics]] | [[Category:Neuroleptics]] | ||
Revision as of 18:00, 19 May 2026
Antipsychotic, Neuroleptic
Quetiapine
Seroquel
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Interactions
Pharmacogenomic + mechanism interactions
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
DPWG guideline: Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers. ClinPGx uses CYP3A4 allele nomenclature as defined by PharmVar , while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the DPWG curation page .
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)
DPWG guideline: Patients who are CYP3A4 poor metabolizers and being treated for depression should be given an alternative drug. Patients being treated for other indications and who are CYP3A4 poor metabolizers should be given a reduced dose of quetiapine. No action is needed for patients who are CYP3A4 intermediate metabolizers. ClinPGx uses CYP3A4 allele nomenclature as defined by PharmVar , while the current version of this guideline issued by the DPWG uses retired allele names. Further details are given on the DPWG curation page .
Rate this interaction. Reports are anonymous and help curate the page.
Clinical relevance: does this interaction matter in practice?trivialcritical
Mechanism description, if it needs work:
Is this row worth surfacing?
Your own experience with this combination:
Experience (1 a little, 5 a lot)
Outcome (-100 worst, +100 best)
Patient experience
No patient-experience reports yet.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Classes
Antipsychotic, Neuroleptic
Pharmacy
Pharmacology
Purported mechanism
D2/5-HT2A antagonist; strong H1 antagonist